Document Detail

Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors.
MedLine Citation:
PMID:  17320518     Owner:  NLM     Status:  MEDLINE    
Increased endocannabinoid (EC) system activity promotes excessive food intake and obesity in animals and humans. The EC system regulates food intake and hedonic reward through central mechanisms located within the hypothalamus and limbic forebrain. In rodent models, cannabinoid1 (CB1) receptor blockade reduces appetite and weight and prevents obesity and insulin resistance. The EC system also regulates food intake and metabolic factors through peripheral CB1 receptors located at multiple sites throughout the body, including adipose tissue, skeletal muscle, liver, and the gastrointestinal (GI) tract. In rodent models, CB1 receptor antagonists act in the liver to decrease lipogenesis, act in the GI tract to increase satiety, and function in adipose tissue to normalize adiponectin levels and reduce fat storage. The CB1 receptor antagonist rimonabant has been shown to reduce food intake and improve metabolic parameters, such as insulin resistance and fatty liver, in animal models of obesity. In preliminary human studies, upregulation of the EC system has been linked to obesity through mechanisms that include high-fat diet, insulin resistance, and genetic malfunction of an EC inactivation enzyme. Evidence suggests that CB1 receptor blockade is a novel therapeutic strategy that addresses the underlying mechanisms of both obesity and cardiometabolic risk.
Stephen C Woods
Related Documents :
20385158 - Decreased food intake following overfeeding involves leptin-dependent and leptin-indepe...
18779298 - Association of the melanocortin-4 receptor v103i polymorphism with dietary intake in se...
20872318 - The mechanism of action for oxyntomodulin in the regulation of obesity.
17449338 - Micronutrient deficiency and the prevalence of mothers' overweight/obesity in egypt.
21322088 - Does the eu sugar policy reform increase added sugar consumption? an empirical evidence...
16367788 - Alterations of arcuate nucleus neuropeptidergic development in contactin-deficient mice...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  The American journal of medicine     Volume:  120     ISSN:  1555-7162     ISO Abbreviation:  Am. J. Med.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-02-26     Completed Date:  2007-04-09     Revised Date:  2007-12-03    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S19-25     Citation Subset:  AIM; IM    
Obesity Research Center at the University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / physiopathology
Disease Models, Animal
Endocannabinoids / physiology*
Fatty Liver / physiopathology
Insulin Resistance / physiology
Obesity / physiopathology*
Receptor, Cannabinoid, CB1 / antagonists & inhibitors,  physiology*
Risk Factors
Grant Support
Reg. No./Substance:
0/Endocannabinoids; 0/Receptor, Cannabinoid, CB1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of card...
Next Document:  Therapeutic options for modifying cardiometabolic risk factors.